Literature DB >> 16494951

Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms.

Paul Ashwood1, Andrew J Wakefield.   

Abstract

Gastrointestinal pathology, characterized by lymphoid nodular hyperplasia and entero-colitis, has been demonstrated in a cohort of children with autistic spectrum disorder (ASD). Systemic and intestinal mucosal immune dysregulation was assessed in ASD children with gastrointestinal (GI) symptoms (n = 18), and typically developing controls (n = 27), including non-inflamed controls (NIC) and inflamed GI control children with Crohn's disease (CD), by analysis of intracellular cytokines in CD3+ lymphocytes. In both peripheral blood and mucosa, CD3+ TNFalpha+ and CD3+ IFNgamma+ were increased in ASD children compared with NIC (p < 0.004) and reached levels similar to CD. In contrast, peripheral and mucosal CD3+ IL-10+ were markedly lower in ASD children with GI symptoms compared with both NIC and CD controls (p < 0.02). In addition, mucosal CD3+ IL-4+ cells were increased (p < 0.007) in ASD compared with NIC. There is a unique pattern of peripheral blood and mucosal CD3+ lymphocytes intracellular cytokines, which is consistent with significant immune dysregulation, in this ASD cohort.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16494951     DOI: 10.1016/j.jneuroim.2005.12.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  65 in total

Review 1.  Microbe hunting.

Authors:  W Ian Lipkin
Journal:  Microbiol Mol Biol Rev       Date:  2010-09       Impact factor: 11.056

Review 2.  Improving the prediction of response to therapy in autism.

Authors:  Stephen Bent; Robert L Hendren
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 3.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

4.  Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders.

Authors:  Paul Ashwood; Paula Krakowiak; Irva Hertz-Picciotto; Robin Hansen; Isaac N Pessah; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2010-11-20       Impact factor: 3.478

5.  Differential monocyte responses to TLR ligands in children with autism spectrum disorders.

Authors:  Amanda M Enstrom; Charity E Onore; Judy A Van de Water; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2009-08-08       Impact factor: 7.217

Review 6.  The power and promise of identifying autism early: insights from the search for clinical and biological markers.

Authors:  Karen Pierce; Stephen J Glatt; Gregory S Liptak; Laura Lee McIntyre
Journal:  Ann Clin Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.567

Review 7.  The role of immune dysfunction in the pathophysiology of autism.

Authors:  Charity Onore; Milo Careaga; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2011-08-28       Impact factor: 7.217

Review 8.  Deficits in bioenergetics and impaired immune response in granulocytes from children with autism.

Authors:  Eleonora Napoli; Sarah Wong; Irva Hertz-Picciotto; Cecilia Giulivi
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

Review 9.  Consensus paper: pathological role of the cerebellum in autism.

Authors:  S Hossein Fatemi; Kimberly A Aldinger; Paul Ashwood; Margaret L Bauman; Charles D Blaha; Gene J Blatt; Abha Chauhan; Ved Chauhan; Stephen R Dager; Price E Dickson; Annette M Estes; Dan Goldowitz; Detlef H Heck; Thomas L Kemper; Bryan H King; Loren A Martin; Kathleen J Millen; Guy Mittleman; Matthew W Mosconi; Antonio M Persico; John A Sweeney; Sara J Webb; John P Welsh
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

10.  Elevated IL-16 expression is associated with development of immune dysfunction in children with autism.

Authors:  Sheikh F Ahmad; Mushtaq A Ansari; Ahmed Nadeem; Saleh A Bakheet; Laila Y Al-Ayadhi; Sabry M Attia
Journal:  Psychopharmacology (Berl)       Date:  2018-11-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.